Optimal Medical Therapy Following Transcatheter Aortic Valve Implantation.

The American Journal of Cardiology
Danon KaewkesRaj Makkar

Abstract

Limited data exist on optimal medical therapy post-transcatheter aortic valve implantation (TAVI) for late cardiovascular events prevention. We aimed to evaluate the benefits of beta-blocker (BB), renin-angiotensin system inhibitor (RASi), and their combination on outcomes following successful TAVI. In a consecutive cohort of 1,684 patients with severe aortic stenosis undergoing TAVI, the status of BB and RASi treatment at discharge was collected, and patients were classified into 4 groups: no-treatment, BB alone, RASi alone, and combination groups. The primary outcome was a composite of all-cause mortality and rehospitalization for heart failure (HHF) at 2-year. There were 415 (25%), 462 (27%), 349 (21%), and 458 (27%) patients in no-treatment, BB alone, RASi alone, and combination groups, respectively. The primary outcome was lower in RASi alone (21%; adjusted hazard ratio [HR]adj: 0.58; 95% confidence interval [CI]: 0.42 to 0.81) and combination (22%; HRadj: 0.53; 95% CI: 0.39 to 0.72) groups than in no-treatment group (34%) but no significant difference between RASi alone and combination groups (HRadj: 1.14; 95% CI: 0.80 to 1.62). The primary outcome results were maintained in a sensitivity analysis of patients with reduced...Continue Reading

References

Oct 12, 2005·Circulation·Hongmei PengNour-Eddine Rhaleb
Jun 7, 2011·The New England Journal of Medicine·Craig R SmithUNKNOWN PARTNER Trial Investigators
Mar 27, 2012·The New England Journal of Medicine·Raj R MakkarUNKNOWN PARTNER Trial Investigators
Jan 7, 2015·Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography·Roberto M LangJens-Uwe Voigt
Apr 5, 2016·The New England Journal of Medicine·Martin B LeonUNKNOWN PARTNER 2 Investigators
Apr 8, 2017·Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography·Helmut BaumgartnerCatherine M Otto
Apr 12, 2017·The American Journal of Cardiology·Chetan P HudedJames D Flaherty
Feb 24, 2018·Journal of the American College of Cardiology·Thomas A TreibelJames C Moon
Dec 5, 2018·JAMA : the Journal of the American Medical Association·Taku InoharaSreekanth Vemulapalli
Mar 19, 2019·The New England Journal of Medicine·Jeffrey J PopmaUNKNOWN Evolut Low Risk Trial Investigators
Mar 19, 2019·The New England Journal of Medicine·Michael J MackUNKNOWN PARTNER 3 Investigators
May 1, 2019·The Annals of Thoracic Surgery·Valentino BiancoIbrahim Sultan
Aug 3, 2019·Journal of the American College of Cardiology·Tania Rodriguez-GabellaIgnacio J Amat-Santos
Jan 30, 2020·The New England Journal of Medicine·Raj R MakkarUNKNOWN PARTNER 2 Investigators
May 16, 2020·Journal of the American College of Cardiology·Katherine H ChauBrian R Lindman
Sep 1, 2020·The New England Journal of Medicine·Jorn BrouwerJurriën M Ten Berg

❮ Previous
Next ❯

Citations

Oct 26, 2021·European Journal of Heart Failure·Ignacio J Amat-SantosUNKNOWN Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) Investigators

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.